HUMA
Humacyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.60
+0.76%Aug 12, 2026, 00:00 UTC
Humacyte, Inc. reported Q2 2026 revenue of $0.4 million and a net loss of $36.8 million, with diluted EPS of -$0.16.
Aug 5, 2026, 23:01 UTC
Humacyte, Inc. (HUMA) shares rose 2.33% to close at $0.73 in the recent trading session.
Source:Jul 27, 2026, 12:00 UTC
Humacyte announced that the FDA accepted its IND application for a first-in-human clinical study of CTEV for coronary artery bypass grafting.
Source:Jun 11, 2026, 00:56 UTC
Humacyte, Inc. commenced an underwritten public offering of its common stock.